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INTRODUCTION
Dementia is a devastating disorder, representing a massive burden on patients and caregivers, as well as on the healthcare and social care system (Chemali et al., 2010) . The majority of dementia patients are elderly people, but alertness for dementia in young patients is increasing (Prince and Jackson, 2009) . Dementia before the age of 65 years is classified as early-onset dementia (EOD) (Lambert et al., 2014) , with as main clinical subtypes Alzheimer's disease (AD), frontotemporal dementia (FTD), dementia with Lewy bodies (DLB) and vascular dementia (VaD) (Masellis et al., 2013) . Characteristic for EOD is the vast clinical and genetic heterogeneity, which poses great diagnostic challenges. Standard criteria for a dementia diagnosis require that the cognitive impairment is sufficiently severe to compromise the social and occupational functioning (Rossor et al., 2010) . Also in research, diagnostic criteria should be adequate to allow stratification of dementia patients into homogeneous groups of patients that most likely are sharing a common biological disease mechanism. The currently used criteria for probable AD, described by the National Institute on Aging -Alzheimer's Association (NIA-AA) (McKhann et al., 2011) , as well as those for probable FTD (Rascovsky et al., 2011) , require the absence of any evidence of other neurodegenerative processes or non-neurological comorbidities that might have a substantial effect on cognition. Due to these stringent exclusion criteria, the sensitivity of the current diagnostic criteria is rather low (Harris et al., 2015) . Also, overlap in symptomatology between different neurodegenerative dementia or other neurodegenerative brain diseases has been documented (Fernández et al., 2017) .
Consequently, at initial clinical presentation and in the early stages of disease, patients may have symptoms that are insufficient or are not specific enough to comply with the diagnostic criteria, resulting in the exclusion of those patients from research studies as well as diagnostic genetic testing.
From a larger prospective study of dementia in Flanders-Belgium initiated in 1995, (Engelborghs et al., 2003) , we selected 211 index patients with symptomatology of dementia at early age. These patients had been excluded from research because of an unclear clinical diagnosis of a specific dementia subtype. At their first clinical consultation, they presented with a cognitive impairment possibly due to neurodegenerative dementia, but their symptoms did not fulfill the criteria for possible or probable dementia of a specified subtype. In this selected patient group, 27.4 % of the index patients had a positive family history of disease. We screened causal genes that are frequently mutated in neurodegenerative brain diseases (NBD), including AD, FTD, amyotrophic lateral sclerosis (ALS), Parkinson's disease (PD) and prion diseases. Identification of a pathogenic mutation might help establishing a more precise clinical diagnosis and might clarify the familial presentation in their family. Perrone F. et al._Manuscript 4 
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Materials and methods
Study population
In a large prospective study on neurodegenerative and vascular dementia in Flanders-Belgium initiated in 1995 (Engelborghs et al., 2003) , patients were ascertained at the Memory Clinic at the general hospitals Middelheim and Hoge Beuken, Hospital Network Antwerp, Antwerp, Belgium.
Index patients were systematically included indifferent of their age, their gender or their clinical dementia subtype. Today, the study counts 4954 participants of whom 3202 received a clinical diagnosis in the dementia spectrum.
A cohort of 741 control individuals was included in the study (Table S1 ), composed of community dwelling volunteers or spouses of patients. Subjective memory complaints, neurologic or psychiatric antecedents and familial history of neurodegeneration were measured by means of a face-to-face personal interview. Cognitive screening was performed using the mini-mental state examination (cutoff score ≥ 26) (Folstein et al., 1975) or the Montreal Cognitive Assessment test (cutoff score >25) (Nasreddine et al., 2005) .
Ethical assurances
We obtained informed consent of patients or their legal guardians and of control persons for their participation in clinical and genetic studies. The study protocols were approved by the ethics committee of the Antwerp University Hospital and the University of Antwerp as well as the hospitals that contributed to the clinical diagnosis and sampling.
Mutation screening
We extracted genomic DNA from whole blood using standard laboratory procedures and performed massive parallel sequencing of the coding sequences of a multi-amplicon gene panel of 16 NBD genes, 15 Mendelian genes and the risk gene APOE (Table S2) . Rare variants with a minor allele frequency (MAF) < 1 % and predicted to affect the protein sequence were selected and validated by Sanger sequencing. Sanger sequencing was also used for exon 5 of PSEN2, which is located in a complex genomic region. The C9orf72 hexanucleotide (G 4 C 2 ) repeat expansion mutation was determined using repeat-primed PCR analysis (Gijselinck et al., 2012) . The allele frequencies of the rare variants, observed in the patient group, were assessed in the control cohort. 
Transcript and protein analyses
To generate cDNA, we extracted total RNA from lymphoblast cells of the PSEN2 p.G359Lfs*74 and LRRK2 p.Leu2063fs* carriers, and three control individuals that were NBD mutation-negative, using the RiboPure TM kit as previously described 
RESULTS
Selected study group
We selected 211 unrelated early-onset patients, with signs of neurodegenerative dementia but lacking a diagnosis of a specific dementia subtype, leaving them with an unclear clinical diagnosis.
The DNA samples and associated clinical diagnoses of those patients were obtained between 1995 and 2015 in the frame of the prospective study on neurodegenerative and vascular dementia in Flanders-Belgium (Engelborghs et al., 2003) , before the use of amyloid PET imaging. The majority of patients were included between 2005 and 2015 (164/211; 77,72 %) ( Figure S1 ). In case of lack of age at onset (AAO) data of the patients, we used a cut-off age at inclusion (AAI) of 70 years, since we observed in the Flanders-Belgian dementia patients (Brouwers et al., 2008) pathogenic mutations in AD genes up to an onset age of 70 years. In the study group, mean onset age or inclusion age was 59.9 ± 8.2 years (range 33-70) and 27.4 % (58/211) had a positive family history (Table S1 ), meaning that they had at least one affected first-degree relative.
Data from clinical history of patients and family, neurological examination, and neuroimaging were collected. Of the rare variant carriers, we summarized in Table 1 the data of the clinical examination and the technical examinations, available in the prospective study at initial neurological consultation.
Mutation screening
Overall, we observed 13 different rare variants in NBD genes in 15 of the 211 unrelated EOD patients (Table 2 ). Six EOD patients (2.84%, 6/211), carried a known pathogenic mutation in five genes i.e.
APP, C9orf72, MAPT, SOD1 and TBK1 (Table 2A) . After the genetic screening, we performed a clinical follow-up of the carriers of a pathogenic mutation, by contacting the referring neurologist to obtain clinical records and results of technical investigations (Table 3 ).
The remaining seven rare variants were labeled as variant of uncertain significance (VUS), and were found in 5 NBD genes i.e. PSEN1, PSEN2, GRN, PRNP and LRRK2 (Table 2B) . Two VUS were novel, a non-synonymous mutation, p.M134I, in PRNP, and an out-frame deletion mutation (c.1073-2delA) in Table 1 ). The other variant in PRNP, p.V209M, was previously reported in a British patient diagnosed with and treated for a psychotic depression, cooccurring with a second variant PRNP p.P105L (Beck et al., 2010) . The authors considered p.V209M a rare polymorphism, which was found coincidentally. In our study, p.V209M was present in three siblings who received a diagnosis of mental retardation, epilepsy and parkinsonism. Taking the heterogeneous phenotypes of the three carriers, a causal role for p.V209M is unlikely.
Patient DR1336 carried two rare variants, the pathogenic p.R406W mutation in MAPT and the p.R71W non-synonymous variant in PSEN2, which was reported as likely benign (ACMG-AMP recommendations; Richards et al., 2015) , and was also present in patient DR1339. Allele-sharing analysis was indicative for a shared haplotype of 10.86 cM between patients DR1336 and DR1339.
The p.R71W variant was observed in one control person (1/741, 0.13%), who did not share the haplotype of the patients.
Expression analysis of the PSEN2 and LRRK2 frameshift mutations
Prediction analysis indicated that the 1 bp-deletion (delA) in PSEN2 (c.1073-2delA; p.G359Lfs*74), abolished the canonical splice acceptor site of exon 12 leading to exon 12 skipping and a frameshift
resulting in a termination codon that falls in the 3'UTR. Amplification of cDNA showed two bands matching in size with the wild type and the predicted mutant transcripts ( Figure 1A) . Quantification of the PSEN2 mutant transcript revealed a 4.4 fold reduced expression compared to wild type ( Figure   1B ). Protein expression analysis showed a reduction of PSEN2 in the mutation carrier compared to controls (Figure 2 ). The inhibition of the proteasome with MG-132 induced a partial accumulation of the PSEN2 in the lymphoblast cells of the mutation carrier, indicating that the mutant PSEN2 protein is translated but unstable and subjected to degradation ( Figure S3 ). However, the mutated protein could not be discriminated from the wild type upon proteasome inhibition: in fact, the predicted molecular weight was 15 kDa for the mutated PSEN2 CTF and 16.58 kDa for the wild type PSEN2 CTF.
Screening of the Belgian AD patient cohort, identified the same PSEN2 variant in another patient (DR1409). Genotyping of flanking polymorphic markers, in the PSEN2 locus, evidenced a common haplotype shared by the two patients (Table S3 ), but absent in 192 Belgian control individuals.
Analysis of in-house NGS data from 849 patients, revealed a low frequency PSEN2 frameshift variant (gnomAD frequency 0.0004062%), located in the same splice acceptor site of exon 12 (PSEN2 c.1073-2_1073-1delAG), predicted also to lead to exon 12 skipping and to the same protein change p.G359Lfs*74. The carrier of this variant had Moroccan origin and received an ALS diagnosis. Figure S4A ) and protein expression analysis on both frontal cortex BA10 and hippocampus showed a reduction of PSEN2 protein in the mutation carrier compared to controls ( Figure S4B ).
The 5-bp deletion in LRRK2 (c.6187_6191delCTCTA; p.L2063fs*) predicted a frameshift and a premature termination codon after amino acid residue 2063. However, cDNA sequencing identified the mutant transcript ( Figure 3B ). Quantification of the mutant and wild-type transcripts revealed a 1.9 fold reduction ( Figure 3A) . Blocking NMD by CHX treatment showed an increase of the LRRK2 mutant transcript ( Figure 3B ). Protein expression analysis in the lymphoblast cells of the patient carrier and mutation negative controls, showed a variable LRRK2 expression ( Figures 3C-S5 ).
Inhibition of the proteasome, did not alter LRRK2 protein expression in the mutation carrier ( Figure   S3 ).
DISCUSSION
We aimed at examining the genetic etiology of patients with clinical symptoms reminiscent of CNS neurodegeneration though insufficient to fulfill the current strict inclusion criteria for the different Perrone F. et al._Manuscript 8 dementia subtypes. These patients with unclear clinical diagnoses were excluded from our cohorts of possible or probable dementia patients that we are using in genetic research. For this pilot study, we analyzed a group of 211 early-onset patients.
Pathogenic mutations
We identified six carriers of a reported pathogenic mutations in five NBD genes which are associated (Cacace et al., 2016) , 18% (Gijselinck et al., 2015) and 17% (Gijselinck et al., 2012) . Two of the pathogenic mutations are In this study, patients DR1331 and DR1332 carried a pathogenic repeat expansion in C9orf72. Patient DR1331 was diagnosed at 48 and patient DR1332 at 66 with MCI (Table 1) . Follow-up clinical data indicated that patient DR1332 was later diagnosed with AD and DLB (Table 3) . DR1332 developed aggressive behavior, comparable to other C9orf72 expansion carriers (Van Mossevelde et al., 2017a) and delusions, characteristic of a DLB phenotype. Rare C9orf72 repeat expansions have been observed in patients clinical diagnosed with AD (Cacace et al., 2013) , as well as pathologically confirmed patients (Kohli et al., 2013 , 2017c) . In addition to the pathogenic MAPT mutation, patient DR1336 also carried the benign variant PSEN2 p.R71W.
Patient DR1330, carrying the APP p.A713T mutation (Table 2) , was diagnosed with MCI at age 67 (Table 1) , which did not change at clinical follow-up due to lack of neurological consultations (Table   3 ). This mutation was also present in one control person DR1422, who was 73 at inclusion, scored 27/30 in the MMSE and had no history of dementia. Allele sharing suggested a shared haplotype of M A N U S C R I P T
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Perrone F. et al._Manuscript 9 2.14 cM. So far, 24 carriers in 11 families have been identified (Sherrington et al., 1996 Armstrong et al., 2004 Rossi et al., 2004; Conidi et al., 2015; Lanoiselé E et al., 2017) . The APP p.A713T carriers present with highly variable onset ages from 52 to 82 years (Rossi et al., 2004) . which is reminiscent of a risk allele of variable penetrance or a modifier. Patient DR1342 carrying the TBK1 p.R127* mutation had memory problems at age 61 (Table 1) and received a diagnosis of AD at clinical followup supported by CSF biomarkers (Table 3) . This TBK1 mutation, was first described in a German patient with sporadic ALS at 70 (van der Zee et al., 2016). The SOD1 p.I114T mutation was identified in patient DR1341 with an initial diagnosis of Korsakoff (Table 1 ) and little extra information at clinical follow-up (Table 3 ). This SOD1 mutation was first identified in two ALS families (Rosen et al., 1993) and later in an extended ALS family showing a high variability of onset age, clinical manifestations, disease progression and penetrance (Lopate et al., 2010) . Patient DR1341 had no motor impairment and there are no case reports of Korsakoff patients carrying a SOD1 mutation.
Variants of uncertain significance
We identified among the seven VUS, five missense variants in causal NBD genes: PSEN1 (n=1), PRNP (n=2) and GRN (n=2) ( Table 2 ) of which contribution to causing disease remains doubtful based on published data as well as our data obtained in this study.
We also observed two VUS carriers of a frameshift mutation, one in PSEN2 (p.G359Lfs*74; c.1073-2delA) in patient DR1340 and one in LRRK2 (p.L2063fs*; c.6187_6191delCTCTA) in patient DR1335 (Table 2 ). In our Belgian AD research cohort, we found a second carrier of the same PSEN2 frameshift mutation in patient DR1409, who shared a common haplotype of 7.57 cM with DR1340.
Patient DR1340 was diagnosed with a multi-domain amnestic MCI (Table 1) , while patient DR1409
presented at age 78 with memory and concentration complaints, which progressed to a global cognitive deterioration most compatible with AD. We also found two additional PSEN2 frameshift mutations by analyzing our in-house available NGS data. In the literature, three frameshift mutations were described in PSEN2 (El Kadmiri et al., 2014; Jayadev et al., 2010) , two of which are debatable (El Kadmiri et al., 2014) . In our study, the carriers of a PSEN2 frameshift mutations had each a different clinical phenotype making it unlikely that these mutations might have a role the pathophysiology of the patients.
The LRRK2 frameshift mutation p.L2063fs*, was reported in a PD patient and in two control individuals (Ross et al., 2011) . The 5-bp deletion occurs in exon 42 of LRRK2, encoding the kinase domain, in which nearly all dominant pathogenic mutations are located (Crosiers et al., 2011) . We measured highly variable LRRK2 protein levels in control individuals, with some showing near null LRRK2 expression, comparable to the LRRK2 loss we observed for the patient carrying of LRRK2 M A N U S C R I P T Perrone F. et al._Manuscript 10 p.L2063fs*. Together, the expression data indicate that this LRRK2 frameshift mutation is unlikely pathogenic.
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Conclusion
In this pilot study, we demonstrated that genetic screening of patients with an unclear phenotype might reveal pathogenic mutations in known NBD causal genes, and provides valuable information that can help clinical diagnosis to obtain a more precise clinical subtype. Additionally, the genetic information can improve our understanding of disease etiology and might help formulating a genetic-based diagnosis. Genetic diagnosis in patients is also relevant for the families of the carriers.
Our results support the hypothesis of the genetic overlap among diverse neurodegenerative brain diseases (Fernández et al., 2017) . Using exome sequencing rather than targeted gene-sequencing is expected to further improve the detection of pathogenic mutations in different NBD genes, though pathogenic copy number variations (CNV) might not be detected. Contrary, exome sequencing will likely produce many more VUS of which the contribution to the disease risk and penetrance remains unknown. In this study, we identified rare VUS, including frameshift mutations, of which the contribution to disease etiology remains unclear and need further functional studies. Also, the finding of VUS in genetic testing might lead to a dilemma on whether or not these results should be communicated (Cauwenberghe et al., 2015) . Nonetheless, our study underscores the importance of massive parallel screening of NBD genes in patients with early-onset of disease independent on their clinical diagnosis to clarify their genetic and clinical etiology. Perrone F. et al._Manuscript 11
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Highlights
• Patients with unclear dementia symptoms at early stages are excluded from research
• 211 Belgian patients with uncertain dementia diagnosis screened for 16 major genes
• We found a six pathogenic mutation in 2.84% of the patients
• We found seven variants of uncertain significance including two frameshift mutations 
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